192 -2 (88) 2026 - Valieva Z.S., Artikova S.G. - INTEGRATIVE APPROACH TO THE DIAGNOSIS OF LIVER FIBROSIS IN THE PROGRESSION OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE

INTEGRATIVE APPROACH TO THE DIAGNOSIS OF LIVER FIBROSIS IN THE PROGRESSION OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE

Valieva Z.S. - Andijan State Medical Institute

Artikova S.G. - Andijan State Medical Institute

Isakova D.Z. - Andijan State Medical Institute

Yunusova Z.V. - Andijan State Medical Institute

Resume

Metabolic dysfunction–associated fatty liver disease (MAFLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to obesity, type 2 diabetes mellitus, and metabolic syndrome. Liver fibrosis represents the principal determinant of disease progression, clinical outcomes, and liver-related mortality in MAFLD. Accurate and timely assessment of fibrosis is therefore critical for risk stratification and therapeutic decision-making. This article reviews current invasive and non-invasive diagnostic modalities for liver fibrosis in MAFLD and highlights the scientific rationale for an integrative diagnostic approach that combines clinical, laboratory, and imaging data to improve diagnostic accuracy and prognostic value.

Keywords: MAFLD, liver fibrosis, non-invasive diagnostics, elastography, integrative approach

First page

1050

Last page

1054

For citation:Valieva Z.S., Artikova S.G., Isakova D.Z., Yunusova Z.V. - INTEGRATIVE APPROACH TO THE DIAGNOSIS OF LIVER FIBROSIS IN THE PROGRESSION OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE//New Day in Medicine 2(88)2026 1050-1054 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. // Nature Reviews Gastroenterology Hepatology. 2013;10(6):330-344. DOI: 10.1038/nrgastro.2013.41.
2. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000. DOI: 10.1002/hep.20920.
3. Byrne C.D., Targher G. NAFLD: A multisystem disease. // Journal of Hepatology. 2015;62(1):47-64. DOI: 10.1016/j.jhep.2014.12.012.
4. Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterology. 2014;5(3):211-218. DOI: 10.1136/flgastro-2013-100403.
5. Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. // Journal of Hepatology. 2020;73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039.
6. Friedman S.L. et al. (2018). Mechanisms of NAFLD development and therapeutic strategies. // Nature Medicine, 2018;24(7):908-922.
7. Lazarus J.V. et al. (2021). Global epidemiology of non-alcoholic fatty liver disease and perspectives on current status and future developments. // Nature Reviews Gastroenterology Hepatology, 2021;18(5):293-308.
8. Loomba R., Adams L.A. (2020). Advances in NAFLD therapeutics. // Nature Reviews Gastroenterology Hepatology, 2020;17(1):11-13.
9. Loomba R. et al. (2021). Emerging mechanisms and potential therapeutics for NAFLD-related fibrosis. // Hepatology 2021;74(2):616-629.
10. Mantovani A., Byrne C.D., Scorletti E. et al. Complications and outcomes of NAFLD and NASH. // Nature Reviews Gastroenterology Hepatology. 2021;18(4):257-267. DOI: 10.1038/s41575-020-00393-9.

    file

    download